Cholesterol and weight in newly diagnosed adult AML
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how cholesterol levels and body weight affect outcomes in adults with newly diagnosed acute myeloid leukemia (AML), a type of blood cancer. It aims to find if these factors influence how well treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been recently diagnosed with acute myeloid leukemia (AML).
- You are healthy enough for standard intensive chemotherapy.
- You are not currently taking cholesterol-lowering medications.
- You do not have diabetes, thyroid problems, or other conditions that affect cholesterol or weight.
- You are not pregnant or breastfeeding.
- You do not have a subtype of AML called acute promyelocytic leukemia (APL).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
This study looks at how adults with acute myeloid leukemia (AML) are treated and how they fare over time. The goal is to better understand the disease and improve care.
This study helps people with newly diagnosed acute myeloid leukemia (AML) by closely monitoring their heart health during chemotherapy. It aims to detect any early heart problems caused by treatment so they can be managed sooner.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Hear when a new BMI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.